West Pharma (WST) Declares $0.13 Quarterly Dividend; 0.6% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
West Announces Fourth-Quarter and Full-Year 2016 Results and Announces Quarterly Dividend
February 16, 2017 7:01 AM ESTEXTON, Pa., Feb. 16, 2017 /PRNewswire/ --Â West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2016 and provided detailed financial guidance for full-year 2017.Â
Executive Summary
Fourth-quarter 2016 reported net sales of $382.3 million grew 6.3% over the prior-year quarter. At constant currency, organic sales growth was 7.7%. Full-year 2016 reported net sales of $1.509 billion grew 7.8% over the prior year. At constant currency, organic sales growth was 9.1%. Fourth-quarter 2016 reported diluted EPS was $0.52 as compared to $0.45 in the prior-year... More
